Sabra Health Care REIT (SBRA) Insider Barbarosh Buys 8,310 Shares
Insider Craig Barbarosh purchased 8,310 shares of Sabra Health Care REIT on June 17, 2026, amid recent insider buying activity.
Reviewed by automated data checks against the source filing. How we make and check alerts
Craig Barbarosh bought 8,310 shares of Sabra Health Care REIT, Inc. ($SBRA) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SBRA is up 5.8% after 1 week, up 11.4% after 1 month and up 8.8% to date (from the $17.78 close on Jun 17, 2026).
Key Points
- Craig Barbarosh bought 8,310 shares of Sabra Health Care REIT, valued at around $150,000 based on a share price of $18.12 on June 17, 2026.
- The stock is currently trading near its 52-week low of $17.17, while analysts maintain a consensus rating of 'buy' with a mean price target of $22.79.
- Sabra Health Care REIT has a dividend yield of 6.04%, with an upcoming earnings report scheduled for November 4, 2026.
Get $SBRA trade alerts by text
We text you when insiders, Congress or big funds trade $SBRA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Sabra Health Care REIT, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Sabra Health Care REIT, Inc.
Craig Barbarosh purchased 8,310 shares of Sabra Health Care REIT, Inc. (NasdaqGS: SBRA) on June 17, 2026. This acquisition is valued at approximately $150,000 based on a share price of $18.12 at the time of the transaction. Barbarosh's buy aligns with a broader trend of insider purchases at the company, which has seen several executives make similar moves on the same day.
Other Insiders Join the Buying
On June 17, multiple insiders at Sabra Health Care REIT also bought 8,310 shares each. This includes Jeffrey Malehorn, Michael Foster, Catherine Cusack, Lynne Katzmann, and Ann Kono. Each of these transactions reflects a collaborative vote of confidence from the company's leadership in its future prospects, although the exact value of these purchases was not disclosed.
Stock Performance and Analyst Ratings
Currently, Sabra Health Care REIT is trading near its 52-week low of $17.17. The stock has fluctuated between a high of $22.77 and the low of $17.17 in the past year. Analysts maintain a consensus 'buy' rating, with a mean price target of $22.79. UBS recently maintained a 'Neutral' rating with a target of $20, while Barclays has been adjusting its targets, most recently setting a target of $21. This mixed sentiment among analysts suggests that while there is optimism, there are also concerns that investors should consider.
Recent Earnings
Sabra Health Care REIT reported revenue of $863.8 million, with a revenue growth of 25.3%. The company has a net margin of 7.6% and an earnings per share (EPS) of $0.26. The next earnings report is scheduled for November 4, 2026, which could provide further insights into the company's financial health and strategy.
What Sabra Health Care REIT, Inc. Does
Sabra Health Care REIT, Inc. is a real estate investment trust that focuses on owning and investing in properties serving the healthcare industry across the U.S. and Canada. The recent insider purchases highlight the confidence among executives in the company's strategy and market position.
What's Ahead for Sabra Health Care REIT, Inc.
Investors will be watching for the upcoming earnings report on November 4, 2026. The recent insider buying activity may indicate a positive outlook for Sabra Health Care REIT, but analysts' mixed ratings suggest caution as well. As always, keep in mind that the latest insider purchases reflect past decisions and may not indicate current positions in the market.
Source: Craig Barbarosh's Form 4 filing on $SBRA (Jun 17, 2026). Find the original filing: SBRA Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts
